INDIA'S PHARMACEUTICAL BUSINESS was a cocktail of ingredients that ranged from success in foreign markets to leadership in a field, from filling supply-chain gaps to making APIs for new drugs. Some companies saw their market capitalisation grow, while some slipped in the BT500 rankings despite doing the right things. Others faced challenges in innovation, regulatory hurdles (read: the US Food & Drug Administration), and market positioning.
CAPITALISING ON GLOBAL TRENDS
Sun Pharmaceutical Industries saw its market capitalisation rise by 45% to ₹3.5 lakh crore, moving up four places in the BT500 ranking, with shareholders seeming to give a thumbs up to its strategies. The company showed steady growth in FY24, with gross sales rising by 10% to ₹47,759 crore. Its formulation sales grew by 9.5% in the domestic market to ₹14,889 crore. The keys to its growth: new products and strategic marketing.
Sun’s formulation sales in the US increased by 13% to ₹15,349 crore. Global speciality sales grew by 19% to ₹8,738 crore, accounting for 18% of total FY24 sales. In emerging markets, it reported formulation sales of ₹8,620 crore, up 9%, and in the Rest of the World (RoW), sales increased by 11% to ₹6,715 crore.
Sun invested ₹3,178 crore in research and development (R&D), up from ₹2,368 crore in FY23. Ebitda or earnings before interest, taxes, depreciation, and amortisation, added up to ₹13,023 crore, with an Ebitda margin of 27%. The adjusted net profit, excluding exceptional items, rose 16.5% to ₹10,071 crore, against ₹8,645 crore the previous year.
Sun Pharma spent ₹793 crore or 6% of total sales on R&D in Q2FY25.
“We remain focussed on maintaining a balanced approach, investing in R&D, and expanding our speciality product portfolio,” said Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, during a recent investor call.
Diese Geschichte stammt aus der December 22, 2024-Ausgabe von Business Today India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der December 22, 2024-Ausgabe von Business Today India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
"Attitude Decides Altitude"
BEST ADVICE - RAJNEET KOHLI, CEO & EXECUTIVE DIRECTOR, BRITANNIA INDUSTRIES LTD
"FOR RATAN TATA, IT WAS ALWAYS NATION FIRST"
Thomas Matthew, former IAS officer, on his new biography of Ratan Tata, the late Chairman Emeritus of Tata Sons
"RADICAL CHANGE NEEDED TO IMPROVE URBAN INFRA"
K.P. Singh, Chairman Emeritus of DLF, on the dynamic nature of the real estate sector, challenges in urban planning, and more
REDEFINING AMBITION
Shashikant Ruia was a visionary entrepreneur who navigated challenges with resilience. He leaves behind a rich legacy of ambition and leadership
ON THE WILD SIDE
LOVE WILDLIFE BUT DON'T WANT TO GIVE UP ON THE FINER THINGS WHILE ON A TRIP TO SPOT ANIMALS? CHECK OUT THESE LUXURIOUS WILDLIFE RESORTS FOR THE HOLIDAY SEASON
"India is the only market globally with substantial growth"
RHI Magnesita CEO Stefan Borgas on the company's M&A strategy, why India is important, the way ahead, and more
FRESH ON THE STREET
IPOs have come back with a bang in 2024, with a record ₹1.3 lakh crore raised till October. As a result, many newly-listed firms have made it to the BT500 list
RIDING THE WAVES
The shipping industry is on the brink of a transformation. Beyond government support and technological advancements, what are the other driving forces and emerging trends that will define the landscape in 2025?
HOME RUN
After a decade-long slowdown, India’s real estate market reached its highest decadal sales level in the first half of 2024
In Pursuit of Good Health
The past year has been eventful for the Indian pharma sector, with some companies witnessing growth, and some challenges. The outlook for the sector, however, remains positive
